HRP20201081T1 - Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe - Google Patents
Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe Download PDFInfo
- Publication number
- HRP20201081T1 HRP20201081T1 HRP20201081TT HRP20201081T HRP20201081T1 HR P20201081 T1 HRP20201081 T1 HR P20201081T1 HR P20201081T T HRP20201081T T HR P20201081TT HR P20201081 T HRP20201081 T HR P20201081T HR P20201081 T1 HRP20201081 T1 HR P20201081T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- acid sequence
- seq
- amino acid
- pharmaceutical preparation
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 16
- 101000797340 Homo sapiens Trem-like transcript 1 protein Proteins 0.000 title 1
- 102100032885 Trem-like transcript 1 protein Human genes 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 5
- 230000004968 inflammatory condition Effects 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 150000007523 nucleic acids Chemical group 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Polipeptid od 6 do 16 aminokiselina koji sadrži najmanje 6 uzastopnih aminokiselina iz aminokiselinske sekvence SEQ ID NO: 4, za uporabu u liječenju upalnog stanja, naznačen time što navedeni polipeptid sadrži aminokiselinsku sekvencu kao što je prikazana u SEQ ID NO: 8.
2. Polipeptid za uporabu prema patentnom zahtjevu 1 koji sadrži aminokiselinsku sekvencu kao što je prikazana u SEQ ID NO: 9.
3. Polipeptid za uporabu prema patentnom zahtjevu 1 koji se sastoji od aminokiselinske sekvence kao što je prikazana u SEQ ID NO: 9.
4. Polipeptid za uporabu prema patentnom zahtjevu 1 koji se sastoji od aminokiselinske sekvence kao što je prikazana u SEQ ID NO: 8.
5. Polipeptid od 6 do 16 aminokiselina koji se sastoji od aminokiselinske sekvence kao što je prikazana u SEQ ID NO: 8 ili koji sadrži aminokiselinsku sekvencu kao što je prikazana u SEQ ID NO: 9.
6. Polipeptid prema patentnom zahtjevu 5 koji se sastoji od aminokiselinske sekvence kao što je prikazana u SEQ ID NO: 9.
7. Polipeptid prema patentnom zahtjevu 5 koji se sastoji od aminokiselinske sekvence kao što je prikazana u SEQ ID NO: 8.
8. Izolirana sekvenca nukleinske kiseline koja kodira polipeptid prema bilo kojem od patentnih zahtjeva 5 do 7.
9. Plazmid koji sadrži sekvencu nukleinske kiseline prema patentnom zahtjevu 8.
10. Ekspresijski vektor koji sadrži sekvencu nukleinske kiseline prema patentnom zahtjevu 8.
11. Polipeptid za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što je upalno stanje sepsa, teška sepsa, septični šok, hemoragijski šok, ishemija-reperfuzija ili pankreatitis.
12. Polipeptid za uporabu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što je upalno stanje septični šok.
13. Farmaceutski pripravak za uporabu u liječenju upalnog stanja, naznačen time što navedeni farmaceutski pripravak sadrži terapeutski efikasnu količinu najmanje jednog polipeptida prema bilo kojem od patentnih zahtjeva 5 do 7, zajedno sa najmanje jednim farmaceutski prihvatljivim ekscipijentom.
14. Farmaceutski pripravak koji sadrži najmanje jedan polipeptid prema bilo kojem od patentnih zahtjeva 5 do 7, ili nukleinsku kiselinu prema patentnom zahtjevu 8, ili plazmid prema patentnom zahtjevu 9 ili ekspresijski vektor prema patentnom zahtjevu 10, zajedno sa najmanje jednim farmaceutski prihvatljivim ekscipijentom.
15. Farmaceutski pripravak za uporabu u liječenju upalnog stanja, naznačen time što navedeni farmaceutski pripravak sadrži terapeutski efikasnu količinu jednog polipeptida od 6 do 16 aminokiselina koji sadrži najmanje 6 uzastopnih aminokiselina iz aminokiselinske sekvence SEQ ID NO: 4, pri čemu navedeni polipeptid sadrži aminokiselinsku sekvencu kao što je prikazana u SEQ ID NO: 8, zajedno sa najmanje jednim farmaceutski prihvatljivim ekscipijentom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305364 | 2010-04-08 | ||
| EP11718957.1A EP2555789B1 (en) | 2010-04-08 | 2011-04-08 | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof |
| PCT/EP2011/055519 WO2011124685A1 (en) | 2010-04-08 | 2011-04-08 | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201081T1 true HRP20201081T1 (hr) | 2021-01-22 |
Family
ID=42262363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201081TT HRP20201081T1 (hr) | 2010-04-08 | 2020-07-09 | Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9255136B2 (hr) |
| EP (2) | EP2555789B1 (hr) |
| JP (2) | JP5918750B2 (hr) |
| CN (1) | CN103153327B (hr) |
| AU (1) | AU2011237851B2 (hr) |
| CA (1) | CA2795390C (hr) |
| CY (1) | CY1123304T1 (hr) |
| DK (1) | DK2555789T3 (hr) |
| ES (1) | ES2805301T3 (hr) |
| HR (1) | HRP20201081T1 (hr) |
| HU (1) | HUE050815T2 (hr) |
| LT (1) | LT2555789T (hr) |
| NZ (1) | NZ602845A (hr) |
| PL (1) | PL2555789T3 (hr) |
| PT (1) | PT2555789T (hr) |
| RS (1) | RS60636B1 (hr) |
| SI (1) | SI2555789T1 (hr) |
| WO (1) | WO2011124685A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104837865B (zh) * | 2012-09-07 | 2019-09-24 | 国立健康与医学研究所 | 衍生自髓样细胞触发受体-1(trem-1)trem-样转录物1(tlt-1)的抑制肽及其用途 |
| KR101404098B1 (ko) * | 2012-11-29 | 2014-06-05 | 성균관대학교산학협력단 | 금속 나노와이어-유기화합물 복합체, 이를 포함하는 필름, 및 이의 제조 방법 |
| JP2018524299A (ja) * | 2015-06-12 | 2018-08-30 | マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル | 免疫応答を調節するための方法およびポリペプチド |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN108276488B (zh) * | 2018-01-26 | 2020-06-19 | 四川农业大学 | 一种鸡髓样细胞触发受体b2多克隆抗体及其制备方法和应用 |
| WO2020036987A1 (en) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
| AU2019348534A1 (en) * | 2018-09-28 | 2021-05-06 | Inotrem | Use of soluble TREM-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy |
| WO2020212415A1 (en) | 2019-04-17 | 2020-10-22 | Novo Nordisk A/S | Bispecific antibodies |
| CN114945580B (zh) * | 2020-01-15 | 2023-12-15 | 北京费森尤斯卡比医药有限公司 | 用于合成南吉博肽的方法 |
| EP4149527A4 (en) * | 2020-05-14 | 2024-07-10 | Ascendo Biotechnology Inc | SELECTIVE TARGETING OF TREML1/MD2 INTERACTION BY SMALL PEPTIDES OR PROTEINS AND ITS USE FOR VACCINE ADJUVANTS |
| JP2023529089A (ja) * | 2020-06-05 | 2023-07-07 | イノトレム | コロナウイルス感染症に罹患した対象の治療に使用するためのｔｒｅｍ－１阻害剤 |
| AU2022287235A1 (en) | 2021-06-02 | 2023-12-14 | Inotrem | Anti-trem-1 antibodies |
| CN113755580B (zh) * | 2021-09-13 | 2023-10-27 | 中国医学科学院阜外医院 | 一种治疗和/或缓解淋巴水肿的药物干预靶点及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2005261A (en) | 1933-05-24 | 1935-06-18 | Leland Electric Co | Riveting machine |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| EP0689601B1 (en) | 1993-02-22 | 2006-10-04 | The Rockefeller University | Production of high titer helper-free retroviruses by transient transfection |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US7129072B1 (en) | 1999-08-30 | 2006-10-31 | New York University | Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor |
| WO2001043695A2 (en) | 1999-10-27 | 2001-06-21 | Cel-Sci Corporation | Peptide constructs for treating autoimmune and related diseases |
| JP2001210726A (ja) * | 2000-01-24 | 2001-08-03 | Hitachi Ltd | 半導体装置及びその製造方法 |
| DE60118362T2 (de) * | 2000-05-19 | 2007-05-24 | The Center for Blood Research, Inc., Boston | VERFAHREN ZUR BEHANDLUNG VON HÄMOSTATISCHEN STÖRUNGEN DURCH LöSLICHES P-SELECTIN |
| JP5324732B2 (ja) * | 2000-05-23 | 2013-10-23 | スネス ファーマシューティカルズ インコーポレイテッド | Ｎｒｇ−２核酸分子、ポリペプチド、ならびに診断および治療法 |
| WO2003020005A2 (en) * | 2001-09-05 | 2003-03-13 | Eli Lilly And Company | Lp mammalian proteins; related reagents |
| US20040180409A1 (en) * | 2003-03-16 | 2004-09-16 | Mcvicar Daniel | TLT-1, a novel platelet-associated receptor and uses therefor |
| GB0426146D0 (en) * | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
| US20130332133A1 (en) | 2006-05-11 | 2013-12-12 | Ramot At Tel Aviv University Ltd. | Classification of Protein Sequences and Uses of Classified Proteins |
| US7553936B2 (en) * | 2006-12-04 | 2009-06-30 | The United States of America as represented by Secretary Department of Health and Human Services | Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions |
| WO2010132370A2 (en) * | 2009-05-11 | 2010-11-18 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Soluble tlt-1 for the treatment and diagnosis of sepsis |
-
2011
- 2011-04-08 HU HUE11718957A patent/HUE050815T2/hu unknown
- 2011-04-08 EP EP11718957.1A patent/EP2555789B1/en active Active
- 2011-04-08 LT LTEP11718957.1T patent/LT2555789T/lt unknown
- 2011-04-08 AU AU2011237851A patent/AU2011237851B2/en active Active
- 2011-04-08 US US13/639,374 patent/US9255136B2/en active Active
- 2011-04-08 ES ES11718957T patent/ES2805301T3/es active Active
- 2011-04-08 CA CA2795390A patent/CA2795390C/en active Active
- 2011-04-08 WO PCT/EP2011/055519 patent/WO2011124685A1/en active Application Filing
- 2011-04-08 JP JP2013503130A patent/JP5918750B2/ja active Active
- 2011-04-08 RS RS20200808A patent/RS60636B1/sr unknown
- 2011-04-08 DK DK11718957.1T patent/DK2555789T3/da active
- 2011-04-08 PT PT117189571T patent/PT2555789T/pt unknown
- 2011-04-08 SI SI201131893T patent/SI2555789T1/sl unknown
- 2011-04-08 PL PL11718957T patent/PL2555789T3/pl unknown
- 2011-04-08 CN CN201180028906.9A patent/CN103153327B/zh active Active
- 2011-04-08 EP EP20176938.7A patent/EP3741383A1/en not_active Withdrawn
- 2011-04-08 NZ NZ602845A patent/NZ602845A/en unknown
-
2015
- 2015-04-29 US US14/699,620 patent/US9815883B2/en active Active
-
2016
- 2016-02-19 JP JP2016029659A patent/JP2016169208A/ja active Pending
-
2020
- 2020-07-09 HR HRP20201081TT patent/HRP20201081T1/hr unknown
- 2020-07-10 CY CY20201100636T patent/CY1123304T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2795390C (en) | 2020-11-03 |
| LT2555789T (lt) | 2020-09-25 |
| DK2555789T3 (da) | 2020-07-20 |
| JP2016169208A (ja) | 2016-09-23 |
| EP2555789A1 (en) | 2013-02-13 |
| CN103153327A (zh) | 2013-06-12 |
| RS60636B1 (sr) | 2020-09-30 |
| US9255136B2 (en) | 2016-02-09 |
| US20160015773A1 (en) | 2016-01-21 |
| AU2011237851A1 (en) | 2012-11-01 |
| US9815883B2 (en) | 2017-11-14 |
| ES2805301T3 (es) | 2021-02-11 |
| CA2795390A1 (en) | 2011-10-13 |
| PT2555789T (pt) | 2020-07-14 |
| CY1123304T1 (el) | 2021-12-31 |
| PL2555789T3 (pl) | 2021-02-08 |
| HUE050815T2 (hu) | 2021-01-28 |
| AU2011237851B2 (en) | 2015-02-05 |
| US20130029921A1 (en) | 2013-01-31 |
| CN103153327B (zh) | 2016-01-20 |
| NZ602845A (en) | 2015-05-29 |
| JP5918750B2 (ja) | 2016-05-18 |
| WO2011124685A1 (en) | 2011-10-13 |
| JP2013523140A (ja) | 2013-06-17 |
| SI2555789T1 (sl) | 2020-10-30 |
| EP2555789B1 (en) | 2020-06-10 |
| EP3741383A1 (en) | 2020-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201081T1 (hr) | Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe | |
| HRP20192314T1 (hr) | Pripravci faktora viii i postupci pripreme i njihove uporabe | |
| JP2012082206A5 (hr) | ||
| MY171146A (en) | Compositions of glp-1 peptides and preparation thereof | |
| JP2015510393A5 (hr) | ||
| NZ587105A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| RU2015112625A (ru) | Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция | |
| NZ598356A (en) | Antigenic tau peptides and uses thereof | |
| WO2012089833A3 (en) | Expression systems | |
| JP2015533791A5 (hr) | ||
| WO2011121289A3 (en) | Peptides and their use | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| WO2013096868A3 (en) | Saposin-a derived peptides and uses thereof | |
| HRP20161009T1 (hr) | Modificirani omci kao inhibitor komplementa | |
| JP2012529293A5 (hr) | ||
| JP2014529399A5 (hr) | ||
| NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| JP2010265269A5 (hr) | ||
| RS54422B1 (en) | APOPTOSIS INHIBITORS AND THEIR USES | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| JP2013542196A5 (hr) | ||
| WO2010103515A3 (en) | Compositions and methods for prevention and treatment of neurodegenerative diseases | |
| JP2018529625A5 (hr) | ||
| JP2019506840A5 (hr) |